Cancer Screening Overview (PDQ®)–Health Professional Version
Potential Benefits and Harms
In 2017, an estimated 1,688,780 people in the United States will be diagnosed with cancer, and 600,920 will die of cancer. Estimates of the premature deaths that could have been avoided through screening vary from 3% to 35%, depending on a variety of assumptions. Beyond the potential for avoiding death, screening may reduce cancer morbidity since treatment for earlier-stage cancers is often less aggressive than that for more advanced-stage cancers.
Several potential harms must be considered against any potential benefit of screening for cancer. Although most cancer screening tests are noninvasive or minimally invasive, some involve small risks of serious complications that may be immediate (e.g., perforation with colonoscopy) or delayed (e.g., potential carcinogenesis from radiation). Another harm is the false-positive test result, which may lead to anxiety and unnecessary invasive diagnostic procedures. These invasive diagnostic procedures carry the risk of serious complications. A less familiar harm is overdiagnosis, i.e., the diagnosis of a condition that would not have become clinically important had it not been detected by screening. This harm is becoming more common as screening tests become more sensitive at detecting tiny tumors. Finally, a false-negative screening test may falsely reassure an individual with subsequent clinical signs or symptoms of cancer and thereby actually delay diagnosis and effective treatment.
A 2009 publication of preliminary results of a cancer screening project in Japan using multiple whole-body screening technologies illustrates clearly the problems of false-positive screening results and potential overdiagnosis.
The project enrolled 1,217 healthy volunteers, aged 35 years and older between August 2003 and July 2004. The volunteers were employees of Hamamatsu Photonics K.K. and affiliated companies in Japan. Participants were enrolled in a company-wide health insurance program and most received mandatory annual employee’s health check-ups for many years, including chest x-ray, fecal occult blood (FOB) testing, upper gastrointestinal series, and mammography screening. Twenty applicants with a prior history of cancer were excluded, leaving 1,197 participants in the evaluation. All enrollees could be considered at low risk for screen-detected cancer.
All participants were offered annual whole body screening by fluorodeoxyglucose positron emission tomography, chest and abdominal computed tomography (CT), brain and pelvic magnetic resonance imaging (MRI), analyses of serum tumor markers including carcinoembryonic antigen, cancer antigen 19-9 (CA19-9), squamous cell carcinoma antigen, prostate specific antigen for men older than aged 50 years, cancer antigen 125 (CA-125) for women, and FOB testing.
Specific clinically relevant classifications were standardized for all test results and imaging tests received three independent readings with consensus resolution (for details refer to ). A screen was classified positive if any test was suggestive of malignancy, and in these cases, the subject was referred to a local hospital for further testing or retesting at the screening center. Interval cancer events were ascertained at subsequent screenings or by interview.
Twenty-two primary cancers were pathologically confirmed, including 18 at the initial screen and one in the second round. Three cancers were diagnosed because of clinical signs and symptoms. The multitest whole body testing overall sensitivity was reported as 81.8% with a specificity of 70.6% (false-positive rate 29.4%) when the results were considered suggestive of malignancy or malignancy could not be definitively ruled out and 68.2% versus 87.4%, respectively, for the more restricted screen classification suggestive of malignancy only.
The incidence of cancers found on the initial screen exceeded the estimated age-matched annual incidence of cancer in Japan by three to four times. Several cancers found on screening were known to be indolent and might be harmless for a long period without affecting cancer mortality.
The possible harms of repeated multimodal cancer screening programs were also assessed using data from the intervention arm of the randomized, controlled Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. A total of 68,436 participants received screening for three cancers, depending on sex, using prostate-specific antigen (PSA), digital rectal exam, transvaginal ultrasound, serum CA-125, chest x-ray, and/or flexible sigmoidoscopy. The study found that after four screening tests (which occurred within a 1-day period in the trial), the cumulative probability of an individual receiving at least one false-positive result was 37% for men and 26% for women. After 14 tests (or 3 years of screening), the probability rose to 60% for men and 49% for women. The cumulative probability of undergoing an invasive procedure as a direct result of a false-positive exam was 29% for men and 22% for women after 14 tests.
The harms of screening are of particular concern in the case of overdiagnosis, as the individual cannot, by definition, reap any potential benefit of screening, but may experience the associated adverse effects, including those of unnecessary treatments. There are two forms of overdiagnosis: 1) the detection of a lesion with essentially no malignant potential (sometimes called “pseudodisease”); and 2) the detection of a lesion that is slow-growing enough that the individual will go on to die of a competing cause of death first. The use of screening tests in individuals with limited life expectancies can therefore be an important cause of overdiagnosis. Studies of current U.S. practice patterns have demonstrated considerable utilization of cancer screening tests in situations where the likelihood of overdiagnosis is high, and benefit very low. For example, investigators linked data from the Surveillance, Epidemiology, and End Results (SEER) cancer registry to Medicare claims in order to evaluate the use of routine cancer screening in persons aged 65 years and older with a known advanced cancer diagnosis (including stage IIIB–IV lung cancer, stage IV colorectal cancer, stage IV gastroesophageal cancer, stage IV breast cancer, and advanced-stage pancreatic cancer). They found 9% of women with established advanced cancer diagnoses received routine screening mammographies and 6% received routine Pap smears; 15% of men with established advanced cancer diagnoses still received routine PSA screening. The strongest individual predictor of routine screening in the setting of advanced cancer was a history of recent screening prior to diagnosis.
There is an association between cancer diagnosis and suicide behavior (either completed or attempted) in the first year after diagnosis. This association has been seen in both adults and young individuals, with relative risk (RR) ranging from 1.6 to 2.0.[6,7]
In developing the cancer screening summaries, the PDQ Screening and Prevention Editorial Board uses the following definitions:
- Screening is a means of detecting disease early in asymptomatic people.
- Positive results of examinations, tests, or procedures used in screening are usually not diagnostic but identify persons at increased risk for the presence of cancer who warrant further evaluation.
- Diagnosis is confirmation of disease by biopsy or tissue examination in the work-up following positive screening tests. (Following a positive screening result, cancer can often be ruled out by procedures other than biopsy or tissue examination.)
The purpose of this summary is to present an explicit evidence-based approach used in the development of the screening summaries. In reaching conclusions, evidence on the balance of risks and benefits is weighed. Cost and cost-effectiveness, however, is not taken into account. Assignment of levels of evidence associated with such screening tests is also discussed.
By design, the PDQ does not issue any clinical practice guidelines. Although many public health organizations present guidelines for health care and screening activities, the quality of these guidelines vary widely, partly because they are opinion based and rely on systematic reviews of evidence that are of varying quality. The best guidelines as assessed by the Appraisal of Guidelines for Research and Evaluation (AGREE) are those based on the best systematic reviews as evaluated by the Assessment of Multiple Systematic Reviews (AMSTAR).
Informed and Shared Medical Decision Making
Guidelines for cancer screening increasingly mention the importance of individuals making informed decisions about participating in screening and sharing in decision making. Unbiased and balanced information about the potential benefits and harms of cancer prevention, screening, and treatment plays an important role in informed decision making by the patient.
In a nationwide survey of informed decision making during patient-provider discussions about colorectal, breast, and prostate cancer screening, patients considered themselves informed but often were not knowledgeable about the risks and benefits of screening. Patients reported that they were usually not asked about their preferences for cancer screening; and although more than 90% of the discussions addressed the pros of screening, 30% or fewer addressed the cons of screening.
For many cancer screening decisions, shared decision making is suggested, whereby the provider helps the patient make an informed, values-based choice from among two or more medically reasonable alternatives.[10,11] This is especially important when screening presents potential harms and limited benefits. There are three components of shared decision making:
- The provider shares screening options with evidence-based information about benefits, harms, and uncertainties.
- The patient shares preferences with the provider, who helps the patient evaluate these options and preferences and make a decision.
- The provider assists with recording and implementing the patient’s preferences.
Patient decision aids can be useful in providing information and helping patients make a decision. They encourage patients to interpret evidence in the context of their own goals and concerns. Decision aids are available in many different formats, including leaflets, booklets, videos, and websites. Some decision aids also include patient stories. Different patients may prefer some formats over others. Most formats encourage patients to make decisions with their physicians. The International Patient Decision Aid Standards (IPDAS) Collaboration has developed a method for evaluating the quality of decision aids.
A Cochrane review of 115 randomized controlled trials of shared decision making supported by decision aids indicated that, in general, decision aids improve patient knowledge about options and risks; reduce decisional conflict related to feeling uninformed or unclear about personal values; and stimulate patients to take more active roles in decision making. In some cases, decisions aids have also been noted to reduce the number of patients choosing major elective invasive surgery over more conservative options, and in fewer patients choosing cancer screening. The effect of using decision aids on the length of consultation varies, ranging from shortening consult time, to no change, to lengthening consult time.
After using a decision aid that included information about breast cancer overdetection, more women made an informed decision about whether they should be screened, and met the threshold for adequate overall knowledge. Compared with controls whose decision aids did not include information about overdetection, fewer women expressed positive attitudes toward screening or intended to be screened in the future. Better-informed individuals may be less likely to choose to participate in cancer screening.
The cancer screening summaries are based on various levels of published scientific evidence and collective clinical experience. The highest level of evidence is taken as mortality reduction in controlled, randomized clinical trials. The results of clinical studies, case-control studies, cohort studies, and other information are also considered in formulating the summaries. In addition, the incidence of cancer, stage distribution, treatment, and mortality rates are considered. The summaries are subject to modification as new evidence becomes available.
The Scientific Basis
At least two requirements must be met for screening to be efficacious:
- A test or procedure must be available to detect cancers earlier than if the cancer were detected as a result of the development of symptoms.
- Evidence must be available that treatment initiated earlier as a consequence of screening results in an improved outcome.
These requirements are necessary but not sufficient to prove the efficacy of screening, which requires a decrease in cause-specific mortality. For example, only one of these two criteria was met in the case of screening for childhood neuroblastoma by the assessment of urinary catecholamine metabolites. A mass screening program was conducted in Saitama Prefecture, Japan, between 1981 and 1992 for 6-month-old infants. During that 12-year period, the annual incidence of neuroblastoma in children younger than 1 year increased from about 28 per million to 260 per million but without a significant reduction in incidence in children older than 1 year. Because there also was no reduction in mortality for the disease, this experience provided strong evidence of overdiagnosis—diagnosis of some neuroblastomas detectable by screening, which would not have been clinically diagnosed later. Similar experiences have been reported elsewhere in Japan  and in the Quebec Neuroblastoma Screening Project (QNSP) in Canada. The history of screening for neuroblastoma also provides a useful illustration of the benefit of undertaking well-designed evaluations of emerging screening technologies before implementing screening programs. Although such studies are very costly, it has been shown that the QNSP itself averted unnecessary morbidity for thousands of children and did so while returning a yield plausibly estimated at a cost savings 64.5 times the investment in the study.
Direct or assisted visual observation is the most widely available examination for the detection of cancer. It is useful in identifying suspicious lesions in the skin, retina, lip, mouth, larynx, external genitalia, and cervix.
The second most available detection procedure is palpation to detect lumps, nodules, or tumors in the breast, mouth, salivary glands, thyroid, subcutaneous tissues, anus, rectum, prostate, testes, ovaries, and uterus and enlarged lymph nodes in the neck, axilla, or groin.
Internal cancers require procedures and tests such as endoscopy, x-rays, MRI, or ultrasound. Laboratory tests, such as the Pap smear or the FOB test have been employed for detection of specific cancers.
The performance of screening tests is usually measured in terms of sensitivity, specificity, and positive-predictive values (PPV) and negative-predictive values (NPV). Sensitivity is the chance that a person with cancer has a positive test. Specificity is the chance a person without cancer has a negative test. PPV is the chance that a person with a positive test has cancer. NPV is the chance that a person with a negative test does not have cancer. PPV and to a lesser degree, NPV are affected by the prevalence of disease in the screened population. For a given sensitivity and specificity, the higher the prevalence, the higher the PPV.
Some individuals are known to be at high risk for cancer, such as those with a personal history of cancer or a strong family history of cancer; increasingly, as genetic mutations and polymorphisms are found to be associated with specific cancers, high-risk individuals will be identified through genetic testing. The type, periodicity, and commencement of screening in high-risk populations for most cancers reflect the judgment of practitioners rather than evidence from scientifically conducted studies. Physician judgment is needed in such circumstances to determine the most appropriate application of available screening methods. Prudence suggests increased vigilance in the higher-risk populations. At a minimum, this means that the high-risk person is identified, is counseled appropriately, and regularly undergoes those screening procedures that have been shown to be of benefit to the general population.
Please refer to the PDQ Adult Treatment summaries for information on cancer recurrence.
For nearly all cancers, treatment options and survival are related to stage, which is generally characterized by the anatomic extent of disease. On this basis, it is assumed that early detection of cancer at an earlier stage may yield better outcomes. In the 1940s, a generalized staging classification of localized, regional, and distant disease was developed to show long-term trends, and it is still useful. In the more detailed TNM system, which has been periodically modified, the (T)umor size, the status of the lymph (N)odes, and the status of distant (M)etastases are also categorized. These elements are grouped into stages 0, I, II, III, and IV according to their association with survival. In general, larger primary malignant tumors have a higher incidence of metastasis to regional lymph nodes and to distant sites. Stage has such a profound effect on outcome that all randomized treatment trials require the comparison of similar stages in evaluating differences in outcome. Shifts in stage may also herald improved survival and decreased mortality, though stage shift alone does not establish benefit.
Biologic cellular characteristics of cancer, such as grade, hormone sensitivity, and gene overexpression are recognized as important predictors of cancer behaviors. For example, high-grade cancer may be fast growing and quick to metastasize regardless of stage at the time of diagnosis. Therefore, detection of these cancers when they are small may not affect outcome. Randomized controlled trials are most definitive in determining screening benefits.
Observed Patterns of Cancer Stage at Diagnosis
The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute gathers cancer incidence data from 11 geographic areas, covering approximately 14% of the U.S. population. These population-based data of long duration (1973–present) are a unique and important resource in monitoring stage-related survival.
Interpreting Changes in Relative Survival Over Time
Increases in survival over time, however, even when based on data from tumor registries, such as SEER that include all cases in a given population, are difficult to interpret. They may reflect the benefits of early detection or improved treatment or both, but they may also result from lead-time bias and overdiagnosis, both of which occur commonly with screening.
Lead-time bias will result in longer estimated survival of people with cancers that have been identified through screening because the time preceding the clinical diagnosis of the cancer is included in the calculation of survival.
Overdiagnosis may result from finding cancers that would never have become manifest clinically. By definition, these cancers have a good prognosis. For example, autopsy series have shown a high percentage of occult early prostate carcinomas in elderly men who died of causes unrelated to prostate cancer. The discovery of these cancers through screening could increase the number of cases and give the appearance of stage shift, and of increases in survival or cure rates, without necessarily reducing mortality. An analysis of data reported by the SEER program between 1950 and 1996 found that changes over time in 5-year relative survival rates for 20 major cancers were essentially unrelated to trends in mortality rates for those cancers over the same period. The authors suggest that changes in 5-year survival rates are largely due to earlier diagnosis and to detection of subclinical cases that might never have surfaced clinically. They conclude that inferences about the effectiveness of early diagnosis or treatment should not be drawn from temporal changes in 5-year survival rates, but rather should be based on changes in mortality rates. Thus, changes in 5-year survival rates or stage shifts are not appropriate measures of the effectiveness of screening for early disease. Reductions in incidence rates for late-stage tumors represent a better measure of progress due to screening than 5-year survival trends, although such evidence is less compelling than reductions in mortality.
Findings from studies carried out using various study designs may be available to support a given summary. The strongest design is the randomized controlled trial. It is, however, not always practical to conduct such a trial to address every question surrounding the field of screening. For each summary of evidence statement, the associated strength of study designs are listed. There are five study designs that are generally used in judging the evidence. In order of strength of design, the five levels are as follows:
- Evidence obtained from randomized controlled trials.
- Evidence obtained from nonrandomized controlled trials.
- Evidence obtained from cohort or case-control studies.
- Evidence obtained from ecologic and descriptive studies (e.g., international patterns studies, time series).
- Opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
Experimental trials are designed to correct for or eliminate selection, lead-time, length, healthy volunteer, and other biases when prospectively testing a detection procedure to determine its effect on health outcome. The highest level of evidence and greatest benefit from screening is mortality reduction in a randomized controlled trial. For most sites, such evidence is not available. Theoretically it is possible to conduct randomized trials for most interventions, but the sample size that is needed, the expense, and the duration of such trials for most cancers, frequently make this approach impractical. Therefore, evidence obtained by other methods is often used.
In certain cases, a preliminary alternative to using mortality reduction to evaluate a new screening modality could be a relatively short-term (e.g., several years) comparison of interval cancer rates observed in a randomized trial comparing the new test and the “standard” screening modality. If the new screening test has the potential to improve disease-specific mortality, repeated applications over a discrete period of time should result in a lower proportion of patients in the intervention arm presenting with symptomatic cancer (of the type screened for) between negative screens. That is, through increased early detection and resulting treatment, the new screening test prevents a higher percentage of clinically important asymptomatic lesions from progressing to overt cancer. Unlike cross-sectional sensitivity comparisons in which study participants receive both new and older screening modalities, this trial design allows for an estimation of the degree of overdiagnosis generated by a screening test. This comparison should take place within the context of a randomized controlled trial.
Case-control and cohort studies provide indirect evidence for the effectiveness of screening, but it is difficult to eliminate the contribution of selection bias and healthy volunteer bias evident in these studies.
Ecological studies can demonstrate association between the use of screening and a stage shift in cancer that can provide indirect evidence of the value of screening. Such evidence is particularly compelling for the effectiveness of screening for cervical cancer. Ecological correlation of mortality and intensity of screening has been used in this context. Such studies do not prove a mortality-reduction effect, and the potential for bias to invalidate inferences from nonexperimental studies or to give misleading results can be substantial.[24-29]
Descriptive uncontrolled studies based on the experience of individual physicians, hospitals, and nonpopulation-based registries may yield some information about screening. The performance characteristics of various detection tests, such as sensitivity, specificity, and PPVs are generally first reported in such descriptive studies. The first evidence that screening may be successful is an increase in the incidence of early cancers and a decreased incidence of late-stage metastatic cancers (stage shift); later, a reduction in deaths may occur. These descriptive studies do not establish efficacy because of the absence of an appropriate control group.
A more detailed description of how the overall evidence regarding benefits and harms of screening tests is graded by the PDQ Screening and Prevention Editorial Board can be found in the PDQ summary on Levels of Evidence for Cancer Screening and Prevention Studies.
Another approach to formulating data about cancer screening is modeling. Models offer the possibility of generating information about cancer screening in circumstances where empiric evidence does not exist. A number of probabilistic and computer simulation models have been developed to do the following:
- Analyze trends in cancer detection and compare these trends with those reported in national or regional databases.
- Investigate the cost-effectiveness of various screening strategies.
- Attempt to estimate overdiagnosis resulting from screening.
A major effort in this area is simulation modeling from the National Cancer Institute's Cancer Intervention and Surveillance Modeling Network (CISNET) program. Models have been developed to investigate the impact of screening for breast, colorectal, lung, prostate, cervical, and esophageal cancers. Examples include a model for prostate screening, which suggests that a combination of changes in prostate cancer treatment, improvements in disease management after primary therapy, and screening contributed to a drop in prostate cancer mortality. Another example models the benefits and harms of breast cancer screening strategies after eight strategies were investigated that included differences by age for the start of screening (40, 45, or 50 years) and screening intervals (annual, biennial, or hybrid). Additionally, an investigation of the benefits and harms of CT lung cancer screening compared 576 different scenarios with varying eligibility criteria (age, pack-years of smoking, years since quitting), screening intervals (1, 2, or 3 years), and the ages of starting (45, 50, 55, or 60 years) and stopping (75, 80, or 85 years) screening.
A serious caveat with all models is that they are only as good as the assumptions upon which they are based, particularly those assumptions about the unknown natural history of the target disease. Many models are complex, so it is difficult to understand how the components interact and how the results are generated. Further, models often do not appropriately account for lead time and length biases and therefore overestimate screening benefit. In addition, models often produce results that are extrapolations beyond the range of the data input to the models. Thus, caution is necessary in interpreting model findings.
Disease-Specific and All-Cause Mortality Endpoints
Disease-specific mortality has been the most widely accepted endpoint in randomized clinical trials of cancer screening; however, the validity of this endpoint rests on the fundamental assumptions that the cause of death can be accurately determined and that the screening and subsequent treatments have negligible effects on other causes of death. Recent reviews of randomized clinical trials of cancer screening suggest that misclassification in cause of death has been a major problem and that misclassification has led to an overestimation of the effectiveness (or an underestimation of the harms) of screening.[33-35] In contrast to disease-specific mortality, all-cause mortality depends only on an accurate ascertainment of deaths and when they occur and therefore is not affected by misclassification in cause of death. One major limitation of the all-cause mortality endpoint, however, is that it is unlikely to reveal a statistically significant effect of cancer screening because this intervention is usually targeted to a disease that causes only a small proportion of all deaths. Nevertheless, all-cause mortality should be considered in conjunction with disease-specific mortality to reduce the possibility that a major harm (or benefit) from screening is hidden by misclassification in cause of death.
An important question, which can be addressed by investigating both endpoints, is whether screening actually saves lives. A systematic review of meta-analyses and randomized trials was performed for diseases in which mortality is a common outcome, including several cancers, to determine whether screening reduced all-cause mortality. Mammography for breast cancer and sigmoidoscopy and fecal occult blood testing for colorectal cancer were the only cancer screening interventions that led to reductions in disease-specific mortality, but there was no test that led to a reduction in all-cause mortality.
Measures of Risk
Several measures of risk are used in cancer research. Absolute risk or absolute rate measures the actual cancer risk or rate in a population or subgroup (e.g., U.S. population, or whites or African Americans). For example, the SEER Program reports risk and rate of cancer in specific geographic areas of the United States.
Rates are often adjusted (e.g., age-adjusted rates) to allow a more accurate comparison of rates over time or among groups. The purpose of the adjustment is to make the groups more alike with respect to important characteristics that may affect the conclusions. For example, when the SEER Program compares cancer rates over time in the United States, the rates are adjusted to one age distribution. If this were not done, cancer rates would seem to increase over time simply because the U.S. population is getting older and the risk of cancer is higher in older age groups.
Relative risk (RR) compares the risk of developing cancer among those who have a particular characteristic or exposure with those who do not. RR is expressed as a ratio of risks or rates; it ranges from infinity to the inverse of infinity (i.e., zero). If the RR is greater than one, the exposure or characteristic is associated with a higher cancer risk; if the RR is one, the exposure and cancer are not associated with one another; if the RR is less than one, the exposure is associated with a lower cancer risk (i.e., the exposure is protective). RR is often used in clinical trials of cancer prevention and screening to estimate the reduction in cancer risk or risk of death, respectively.
An odds ratio (OR) is often used as an estimate of the RR. It, too, indicates whether there is an association between an exposure or characteristic and cancer. It compares the odds of an exposure or characteristic among cancer cases with the odds among a comparison group without cancer. Although not as intuitively understood as rates or risk, OR is used because it is statistically more valid in some settings when other measures of risk are not valid. For relatively uncommon events/diseases such as a cancer diagnosis, it can be interpreted like a RR is interpreted; however, it becomes a progressively inaccurate estimate of the RR as the underlying absolute risk of disease in the population under study rises above 10%. ORs are typically used in case-control studies to identify potential risk factors or protective factors for cancer.
Risk or rate difference (or excess risk) compares the actual cancer risk or rate among at least two groups of people, based on an important characteristic or exposure, by subtracting the risks or rates from one another (e.g., subtracting lung cancer rates among nonsmokers from that of cigarette smokers estimates the excess risk of lung cancer due to smoking). This can be used in public health to estimate the number of cancer cases that could be avoided if an exposure were reduced or eliminated in the population.
Population-attributable risk measures the proportion of cancers that can be attributed to a particular exposure or characteristic. It combines information about the RR of cancer associated with a particular exposure and the prevalence of that exposure in the population, and estimates the proportion of cancer cases in a population that could be avoided if an exposure were reduced or eliminated.
Number needed to screen estimates the number of people that must participate in a screening program for one death to be prevented over a defined time interval.
Average life-years saved estimates the number of years that an intervention saves, on average, for an individual who receives the intervention. This reflects mortality reduction and life extension (or avoidance of premature deaths).
- American Cancer Society: Cancer Facts and Figures 2017. Atlanta, Ga: American Cancer Society, 2017. Available online. Last accessed March 7, 2018.
- Kramer BS: The science of early detection. Urol Oncol 22 (4): 344-7, 2004 Jul-Aug. [PUBMED Abstract]
- Nishizawa S, Kojima S, Teramukai S, et al.: Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report. J Clin Oncol 27 (11): 1767-73, 2009. [PUBMED Abstract]
- Croswell JM, Kramer BS, Kreimer AR, et al.: Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7 (3): 212-22, 2009 May-Jun. [PUBMED Abstract]
- Sima CS, Panageas KS, Schrag D: Cancer screening among patients with advanced cancer. JAMA 304 (14): 1584-91, 2010. [PUBMED Abstract]
- Lu D, Fall K, Sparén P, et al.: Suicide and suicide attempt after a cancer diagnosis among young individuals. Ann Oncol 24 (12): 3112-7, 2013. [PUBMED Abstract]
- Baade PD, Fritschi L, Eakin EG: Non-cancer mortality among people diagnosed with cancer (Australia). Cancer Causes Control 17 (3): 287-97, 2006. [PUBMED Abstract]
- Burda BU, Norris SL, Holmer HK, et al.: Quality varies across clinical practice guidelines for mammography screening in women aged 40-49 years as assessed by AGREE and AMSTAR instruments. J Clin Epidemiol 64 (9): 968-76, 2011. [PUBMED Abstract]
- Hoffman RM, Lewis CL, Pignone MP, et al.: Decision-making processes for breast, colorectal, and prostate cancer screening: the DECISIONS survey. Med Decis Making 30 (5 Suppl): 53S-64S, 2010 Sep-Oct. [PUBMED Abstract]
- O'Connor AM, Llewellyn-Thomas HA, Flood AB: Modifying unwarranted variations in health care: shared decision making using patient decision aids. Health Aff (Millwood) Suppl (Variation): VAR63-72, 2004. [PUBMED Abstract]
- Charles C, Gafni A, Whelan T: Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 44 (5): 681-92, 1997. [PUBMED Abstract]
- Coulter A, Collins A: Making Shared Decision-Making a Reality: No Decision About Me, Without Me. London, UK: The King's Fund, 2011. Also available online. Last accessed April 21, 2017.
- Elwyn G, O'Connor A, Stacey D, et al.: Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ 333 (7565): 417, 2006. [PUBMED Abstract]
- Stacey D, Hawker G, Dervin G, et al.: Decision aid for patients considering total knee arthroplasty with preference report for surgeons: a pilot randomized controlled trial. BMC Musculoskelet Disord 15: 54, 2014. [PUBMED Abstract]
- Hersch J, Barratt A, Jansen J, et al.: Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet 385 (9978): 1642-52, 2015. [PUBMED Abstract]
- Yamamoto K, Hayashi Y, Hanada R, et al.: Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan. J Clin Oncol 13 (8): 2033-8, 1995. [PUBMED Abstract]
- Bessho F: Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 67 (4): 520-2, 1996. [PUBMED Abstract]
- Woods WG, Tuchman M, Robison LL, et al.: A population-based study of the usefulness of screening for neuroblastoma. Lancet 348 (9043): 1682-7, 1996 Dec 21-28. [PUBMED Abstract]
- Soderstrom L, Woods WG, Bernstein M, et al.: Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening. J Natl Cancer Inst 97 (15): 1118-24, 2005. [PUBMED Abstract]
- Woolf SH: Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. N Engl J Med 333 (21): 1401-5, 1995. [PUBMED Abstract]
- Welch HG, Schwartz LM, Woloshin S: Are increasing 5-year survival rates evidence of success against cancer? JAMA 283 (22): 2975-8, 2000. [PUBMED Abstract]
- Irwig L, Houssami N, Armstrong B, et al.: Evaluating new screening tests for breast cancer. BMJ 332 (7543): 678-9, 2006. [PUBMED Abstract]
- Hakama M, Miller AB, Day NE, eds.: Screening for cancer of the uterine cervix. Lyon, France: International Agency for Research on Cancer, 1986.
- Connor RJ, Prorok PC, Weed DL: The case-control design and the assessment of the efficacy of cancer screening. J Clin Epidemiol 44 (11): 1215-21, 1991. [PUBMED Abstract]
- Friedman DR, Dubin N: Case-control evaluation of breast cancer screening efficacy. Am J Epidemiol 133 (10): 974-84, 1991. [PUBMED Abstract]
- Janzon L, Andersson I: The Malmo mammographic screening trial. In: Miller AB, Chamberlain J, Day NE, et al., eds.: Cancer Screening. Cambridge: Cambridge University Press, 1991, pp 37-44.
- Moss SM: Case-control studies of screening. Int J Epidemiol 20 (1): 1-6, 1991. [PUBMED Abstract]
- Weiss NS, Lazovich D: Case-control studies of screening efficacy: the use of persons newly diagnosed with cancer who later sustain an unfavorable outcome. Am J Epidemiol 143 (4): 319-22, 1996. [PUBMED Abstract]
- Suzuki KJ, Nakaji S, Tokunaga S, et al.: Confounding by dietary factors in case-control studies on the efficacy of cancer screening in Japan. Eur J Epidemiol 20 (1): 73-8, 2005. [PUBMED Abstract]
- Etzioni R, Gulati R, Tsodikov A, et al.: The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 118 (23): 5955-63, 2012. [PUBMED Abstract]
- Mandelblatt JS, Stout NK, Schechter CB, et al.: Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med 164 (4): 215-25, 2016. [PUBMED Abstract]
- de Koning HJ, Meza R, Plevritis SK, et al.: Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med 160 (5): 311-20, 2014. [PUBMED Abstract]
- Black WC: Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 92 (16): 1280-2, 2000. [PUBMED Abstract]
- Olsen O, Gøtzsche PC: Screening for breast cancer with mammography. Cochrane Database Syst Rev (4): CD001877, 2001. [PUBMED Abstract]
- Black WC, Haggstrom DA, Welch HG: All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94 (3): 167-73, 2002. [PUBMED Abstract]
- Saquib N, Saquib J, Ioannidis JP: Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. Int J Epidemiol 44 (1): 264-77, 2015. [PUBMED Abstract]
Changes to This Summary (04/21/2017)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Updated statistics with estimated new cases and deaths for 2017 (cited American Cancer Society as reference 1).
Added text to state that three cancers were diagnosed because of clinical signs and symptoms.
This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.
About This PDQ Summary
Purpose of This Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Reviewers and Updates
This summary is reviewed regularly and updated as necessary by the PDQ Screening and Prevention Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).
Board members review recently published articles each month to determine whether an article should:
- be discussed at a meeting,
- be cited with text, or
- replace or update an existing article that is already cited.
Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.
Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.
Levels of Evidence
Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Screening and Prevention Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.
Permission to Use This Summary
PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”
The preferred citation for this PDQ summary is:
PDQ® Screening and Prevention Editorial Board. PDQ Cancer Screening Overview. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/about-cancer/screening/hp-screening-overview-pdq. Accessed <MM/DD/YYYY>. [PMID: 26389235]
Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.
The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.
More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.